A panel of independent expert advisers on obstetric and reproductive drugs will meet starting Monday to decide whether to recommend that Makena, an injection marketed as lowering the risk of preterm birth, remain available for at least some patients.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
